Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

Published

Oct 20, 2025 8:01am EDT

Novel combination including eftilagimod alfa (efti) in neoadjuvant setting drives 51.5% tumour hyalinization/fibrosis in patients with soft tissue sarcoma (p
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

IMMP

View as Table

now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Stocks, Funds, ETFs and more asset classes.

View as Table

now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Shares, Indexes, ETP and more asset classes.

Edit Watchlist

Your Watchlist is empty.

Create your Watchlist to save your favorite quotes on Nasdaq.com. Log in or create a free account to get started.